vs

Side-by-side financial comparison of Apollo Commercial Real Estate Finance, Inc. (ARI) and PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (PACB). Click either name above to swap in a different company.

Apollo Commercial Real Estate Finance, Inc. is the larger business by last-quarter revenue ($73.3M vs $44.6M, roughly 1.6× PACIFIC BIOSCIENCES OF CALIFORNIA, INC.). Apollo Commercial Real Estate Finance, Inc. runs the higher net margin — 39.9% vs -90.4%, a 130.3% gap on every dollar of revenue. On growth, PACIFIC BIOSCIENCES OF CALIFORNIA, INC. posted the faster year-over-year revenue change (13.8% vs 4.0%). Over the past eight quarters, PACIFIC BIOSCIENCES OF CALIFORNIA, INC.'s revenue compounded faster (7.3% CAGR vs -4.6%).

Apollo Commercial Real Estate Finance, Inc. is a real estate investment trust that originates, acquires and manages commercial real estate debt assets including mortgages, mezzanine loans and mortgage-backed securities, primarily operating in the U.S. market to deliver consistent risk-adjusted returns.

Pacific Biosciences of California, Inc. is an American biotechnology company founded in 2004 that develops and manufactures systems for gene sequencing and some novel real time biological observation. PacBio has two principal sequencing platforms: single-molecule real-time sequencing (SMRT), based on the properties of zero-mode waveguides and sequencing by binding (SBB) chemistry, which uses native nucleotides and scarless incorporation for DNA binding and extension.

ARI vs PACB — Head-to-Head

Bigger by revenue
ARI
ARI
1.6× larger
ARI
$73.3M
$44.6M
PACB
Growing faster (revenue YoY)
PACB
PACB
+9.9% gap
PACB
13.8%
4.0%
ARI
Higher net margin
ARI
ARI
130.3% more per $
ARI
39.9%
-90.4%
PACB
Faster 2-yr revenue CAGR
PACB
PACB
Annualised
PACB
7.3%
-4.6%
ARI

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
ARI
ARI
PACB
PACB
Revenue
$73.3M
$44.6M
Net Profit
$29.2M
$-40.4M
Gross Margin
37.1%
Operating Margin
39.7%
-92.3%
Net Margin
39.9%
-90.4%
Revenue YoY
4.0%
13.8%
Net Profit YoY
-28.2%
-1802.7%
EPS (diluted)
$0.19
$-0.11

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ARI
ARI
PACB
PACB
Q4 25
$73.3M
$44.6M
Q3 25
$61.6M
$38.4M
Q2 25
$70.9M
$39.8M
Q1 25
$65.8M
$37.2M
Q4 24
$70.5M
$39.2M
Q3 24
$71.6M
$40.0M
Q2 24
$81.1M
$36.0M
Q1 24
$80.5M
$38.8M
Net Profit
ARI
ARI
PACB
PACB
Q4 25
$29.2M
$-40.4M
Q3 25
$50.8M
$-38.0M
Q2 25
$20.7M
$-41.9M
Q1 25
$26.0M
$-426.1M
Q4 24
$40.7M
$2.4M
Q3 24
$-91.5M
$-60.7M
Q2 24
$35.8M
$-173.3M
Q1 24
$-104.5M
$-78.2M
Gross Margin
ARI
ARI
PACB
PACB
Q4 25
37.1%
Q3 25
41.4%
Q2 25
36.9%
Q1 25
-3.7%
Q4 24
25.6%
Q3 24
25.0%
Q2 24
16.5%
Q1 24
29.1%
Operating Margin
ARI
ARI
PACB
PACB
Q4 25
39.7%
-92.3%
Q3 25
82.8%
-101.1%
Q2 25
29.4%
-112.8%
Q1 25
39.7%
-1154.5%
Q4 24
57.9%
-390.1%
Q3 24
-127.8%
-160.3%
Q2 24
44.2%
-488.3%
Q1 24
-129.6%
-209.6%
Net Margin
ARI
ARI
PACB
PACB
Q4 25
39.9%
-90.4%
Q3 25
82.4%
-98.9%
Q2 25
29.3%
-105.4%
Q1 25
39.5%
-1146.8%
Q4 24
57.7%
6.0%
Q3 24
-127.9%
-151.9%
Q2 24
44.1%
-481.3%
Q1 24
-129.8%
-201.4%
EPS (diluted)
ARI
ARI
PACB
PACB
Q4 25
$0.19
$-0.11
Q3 25
$0.34
$-0.13
Q2 25
$0.12
$-0.14
Q1 25
$0.16
$-1.44
Q4 24
$0.25
$-0.44
Q3 24
$-0.69
$-0.22
Q2 24
$0.23
$-0.64
Q1 24
$-0.76
$-0.29

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ARI
ARI
PACB
PACB
Cash + ST InvestmentsLiquidity on hand
$139.8M
$279.5M
Total DebtLower is stronger
Stockholders' EquityBook value
$1.9B
$5.3M
Total Assets
$9.9B
$784.1M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ARI
ARI
PACB
PACB
Q4 25
$139.8M
$279.5M
Q3 25
$245.9M
$298.7M
Q2 25
$177.6M
$314.7M
Q1 25
$166.4M
$343.1M
Q4 24
$317.4M
$389.9M
Q3 24
$194.3M
$471.1M
Q2 24
$174.7M
$509.8M
Q1 24
$161.2M
$561.9M
Stockholders' Equity
ARI
ARI
PACB
PACB
Q4 25
$1.9B
$5.3M
Q3 25
$1.9B
$36.1M
Q2 25
$1.8B
$61.5M
Q1 25
$1.9B
$91.6M
Q4 24
$1.9B
$506.6M
Q3 24
$1.9B
$453.1M
Q2 24
$2.0B
$492.7M
Q1 24
$2.0B
$649.0M
Total Assets
ARI
ARI
PACB
PACB
Q4 25
$9.9B
$784.1M
Q3 25
$9.5B
$803.2M
Q2 25
$9.8B
$825.5M
Q1 25
$8.8B
$860.8M
Q4 24
$8.4B
$1.3B
Q3 24
$9.1B
$1.5B
Q2 24
$9.3B
$1.5B
Q1 24
$9.2B
$1.7B

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ARI
ARI
PACB
PACB
Operating Cash FlowLast quarter
$142.5M
$-19.1M
Free Cash FlowOCF − Capex
$-19.9M
FCF MarginFCF / Revenue
-44.6%
Capex IntensityCapex / Revenue
1.9%
Cash ConversionOCF / Net Profit
4.88×
TTM Free Cash FlowTrailing 4 quarters
$-114.1M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ARI
ARI
PACB
PACB
Q4 25
$142.5M
$-19.1M
Q3 25
$31.7M
$-18.7M
Q2 25
$63.2M
$-29.4M
Q1 25
$39.3M
$-44.1M
Q4 24
$200.3M
$-30.6M
Q3 24
$47.2M
$-45.5M
Q2 24
$50.2M
$-54.3M
Q1 24
$52.8M
$-75.7M
Free Cash Flow
ARI
ARI
PACB
PACB
Q4 25
$-19.9M
Q3 25
$-18.8M
Q2 25
$-29.9M
Q1 25
$-45.4M
Q4 24
$-32.3M
Q3 24
$-46.3M
Q2 24
$-55.7M
Q1 24
$-79.6M
FCF Margin
ARI
ARI
PACB
PACB
Q4 25
-44.6%
Q3 25
-48.9%
Q2 25
-75.3%
Q1 25
-122.3%
Q4 24
-82.3%
Q3 24
-115.7%
Q2 24
-154.8%
Q1 24
-205.0%
Capex Intensity
ARI
ARI
PACB
PACB
Q4 25
1.9%
Q3 25
0.2%
Q2 25
1.4%
Q1 25
3.7%
Q4 24
4.1%
Q3 24
2.0%
Q2 24
4.1%
Q1 24
10.0%
Cash Conversion
ARI
ARI
PACB
PACB
Q4 25
4.88×
Q3 25
0.62×
Q2 25
3.05×
Q1 25
1.51×
Q4 24
4.93×
-12.93×
Q3 24
Q2 24
1.40×
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

ARI
ARI

Segment breakdown not available.

PACB
PACB

Products$39.0M87%
Service And Other$5.7M13%

Related Comparisons